文献速递白血病

早期外周血原始细胞清除率预测急性髓系白血病微小残留病状态并细化疾病预后

Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2020-08-19

研究纳入2007至2014年按NILG 02-06试验治疗并获完全缓解的120例急性髓系白血病患者,整合微小残留病(MRD)与外周血原始细胞清除率(PBC)评估。PBC以1.5-log阈值分组后,诱导后MRD1与巩固后MRD2阴性率显著不同;PBChigh/MRD1neg组MRD2阴性率90%,3年DFS与OS分别为68%和76%;PBClow/MRD1pos组则分别为20%、34%和24%。MRD2仅在PBC/MRD1结果不一致时增加预后价值。

要点

  • PBC以1.5-log阈值分组后,诱导后与巩固后MRD阴性率显著不同。
  • PBChigh/MRD1neg组MRD2阴性率90%,3年DFS 68%、OS 76%。
  • PBClow/MRD1pos组MRD2阴性率20%,3年DFS 34%、OS 24%。

核心结论

  • PBC联合MRD1可提前反映MRD2相关信息,支持按个体化疗敏感性确定基于MRD的治疗决策时机,该思路已用于GIMEMA即将开展的前瞻性多中心试验。

研究设计与样本

  • 研究纳入2007至2014年按NILG 02-06试验治疗、诱导后达完全缓解的120例急性髓系白血病患者,将MRD与PBC整合评估。

主要发现

  • PBC以1.5-log阈值分组后,各组在诱导后(MRD1)或巩固后(MRD2)达到MRD阴性的概率显著不同。
  • PBChigh/MRD1neg组MRD2阴性率为90%,3年DFS估计为68%、OS估计为76%。
  • PBClow/MRD1pos组MRD2阴性率为20%,3年DFS为34%、OS为24%。
  • MRD2仅在PBC与MRD1数据不一致的病例中增加预后价值。

关键数值与推荐

  • PBC分组采用1.5-log阈值。
  • PBChigh/MRD1neg组:MRD2阴性率90%,3年DFS 68%,3年OS 76%。
  • PBClow/MRD1pos组:MRD2阴性率20%,3年DFS 34%,3年OS 24%。

临床怎么用

  • 作者支持基于个体化疗敏感性合理安排MRD决策时机,并已将这一思路用于GIMEMA即将开展的前瞻性多中心试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) is increasingly used in risk stratification. However, several issues around this use are unresolved, including, among others, the most suitable time-point(s) for its application. Overall, late assessments appear more effective at distinguishing outcome but, in some studies, the early evaluations were already highly informative, anticipating the value of later ones. Our work integrated MRD with peripheral blast clearance (PBC), a treatment-related biomarker previously demonstrated to be a powerful predictor of response. From 2007 to 2014, we have studied 120 patients treated according to the NILG 02-06 trial and who achieved CR after induction. Patients in PBC-defined categories (separated by a 1.5-log threshold) showed significantly different probabilities of attaining MRD negativity, after either induction (MRD1) or consolidation (MRD2). Peripheral blast clearance combined with MRD1 largely anticipated MRD2-related information: when both biomarkers predicted chemosensitive disease (PBChigh /MRD1neg ), the rate of MRD2-negativity was 90%, and DFS and OS estimates were 68% and 76% at 3 years, respectively. When both markers were unfavorable (PBClow /MRD1pos ), rates of MRD2 negativity, DFS, and OS were 20%, 34%, and 24%, respectively, at 3 years. In fact, MRD2 added prognostic value only in cases with discordant PBC/MRD1 data. Our data support a reasoned timing for MRD-based therapeutic decisions, modulated on individual chemosensitivity, an approach we have implemented in a forthcoming prospective multi-center trial by Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mannelli F, Gianfaldoni G, Bencini S, et al. Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. Am J Hematol. 2020. PMID: 32697337. doi:10.1002/ajh.25942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。